X

Drug Profile

Research programme - anti-cancer therapeutics - Gnubiotics Sciences

Latest Information Update: 15 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gnubiotics Sciences
Class Antineoplastics; Glycopeptides
Mechanism of Action Microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Colorectal cancer; Skin cancer

Most Recent Events

15 Oct 2024 Gnubiotics Sciences receives patent allowance for glycopeptide-rich compositions in USA
06 Jul 2022 Gnubiotics Sciences collaborates with University Hospital Zurich for the development of the glycopeptides for the treatment of solid tumours
15 Oct 2021 Preclinical trials in Colorectal cancer in Switzerland (PO) (Gnubiotics pipeline, October 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com